Free Trial
NASDAQ:MESO

Mesoblast (MESO) Stock Price, News & Analysis

Mesoblast logo
$11.61 -0.09 (-0.77%)
(As of 11:22 AM ET)

About Mesoblast Stock (NASDAQ:MESO)

Key Stats

Today's Range
$11.39
$12.00
50-Day Range
$6.10
$11.71
52-Week Range
$1.61
$12.18
Volume
97,411 shs
Average Volume
768,391 shs
Market Capitalization
$1.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.50
Consensus Rating
Buy

Company Overview

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Mesoblast Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
17th Percentile Overall Score

MESO MarketRank™: 

Mesoblast scored higher than 17% of companies evaluated by MarketBeat, and ranked 926th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Mesoblast has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Mesoblast has only been the subject of 3 research reports in the past 90 days.

  • Read more about Mesoblast's stock forecast and price target.
  • Earnings Growth

    Earnings for Mesoblast are expected to grow in the coming year, from ($0.74) to ($0.57) per share.

  • Price to Book Value per Share Ratio

    Mesoblast has a P/B Ratio of 2.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.22% of the outstanding shares of Mesoblast have been sold short.
  • Short Interest Ratio / Days to Cover

    Mesoblast has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

    Short interest in Mesoblast has recently increased by 11.20%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Mesoblast does not currently pay a dividend.

  • Dividend Growth

    Mesoblast does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.22% of the outstanding shares of Mesoblast have been sold short.
  • Short Interest Ratio / Days to Cover

    Mesoblast has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

    Short interest in Mesoblast has recently increased by 11.20%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Mesoblast has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Mesoblast this week, compared to 3 articles on an average week.
  • Search Interest

    Only 7 people have searched for MESO on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Mesoblast to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Mesoblast insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    18.80% of the stock of Mesoblast is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 1.43% of the stock of Mesoblast is held by institutions.

  • Read more about Mesoblast's insider trading history.
Receive MESO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

MESO Stock News Headlines

DeFi Coin on Verge of Breakout!
The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years.
Mesoblast Advances Cellular Medicines Amid FDA Hopes
See More Headlines

MESO Stock Analysis - Frequently Asked Questions

Mesoblast's stock was trading at $2.20 at the start of the year. Since then, MESO shares have increased by 432.0% and is now trading at $11.7050.
View the best growth stocks for 2024 here
.

Mesoblast Limited (NASDAQ:MESO) announced its quarterly earnings data on Wednesday, August, 30th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.06. The firm earned $2.14 million during the quarter, compared to analysts' expectations of $2 million.

Shares of Mesoblast reverse split on Friday, January 5th 2024. The 1-2 reverse split was announced on Friday, January 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split.

Mesoblast (MESO) raised $69 million in an IPO on Friday, November 13th 2015. The company issued 5,700,000 shares at a price of $12.10 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

Top institutional investors of Mesoblast include Lazari Capital Management Inc. (0.04%), XY Capital Ltd (0.03%), Creative Planning (0.02%) and Perkins Coie Trust Co (0.01%).

Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mesoblast investors own include NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Meta Platforms (META), CRISPR Therapeutics (CRSP) and Corbus Pharmaceuticals (CRBP).

Company Calendar

Last Earnings
8/30/2023
Today
11/14/2024
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MESO
Previous Symbol
OTCMKTS:MBLTY
Employees
80
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.50
High Stock Price Target
$12.00
Low Stock Price Target
$11.00
Potential Upside/Downside
-1.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.90 million
Book Value
$4.21 per share

Miscellaneous

Free Float
92,713,000
Market Cap
$1.34 billion
Optionable
Optionable
Beta
3.47

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:MESO) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners